Indications
Each indication opens its study.
Immune & inflammation
Metabolic Diseases
CNS & addiction
Stage of development
-
PNB-001
COVID-19 Lung InflammationCCK ligand, lymphokine
- Molecule
- PNB-001
- Indication
- COVID-19 Lung Inflammation
- Biological action
- CCK ligand, lymphokine
- Status
- Phase 3 approved · currently stopped because of the Omicron variant
-
PNB-001
Ulcerative ColitisCCK ligand, lymphokine, T-cell activation
- Molecule
- PNB-001
- Indication
- Ulcerative Colitis
- Biological action
- CCK ligand, lymphokine, T-cell activation
- Status
- Phase 3 submission
-
PNB-001
Crohn's DiseaseCCK ligand, lymphokine, T-cell activation
- Molecule
- PNB-001
- Indication
- Crohn's Disease
- Biological action
- CCK ligand, lymphokine, T-cell activation
- Status
- Phase 2 completed
-
PNB-001
Type 2 DiabetesCCK-mediated blood glucose reduction; restoration of pancreatic cells
- Molecule
- PNB-001
- Indication
- Type 2 Diabetes
- Biological action
- CCK-mediated blood glucose reduction; restoration of pancreatic cells
- Status
- Phase 2 submission
-
- Molecule
- PNB-001
- Indication
- Dementia
- Biological action
- CCK-mediated release of acetylcholine (ACh)
- Status
- Phase 2 ready
- Target and mechanism
- CCK-A agonist with CCK-B (CCK2/gastrin) antagonist properties, described by the company as first in class. Acts as a lymphokine, raising CD4 and CD8 T cells.
- Key findings
Phase 1 (single and multiple ascending dose) completed in 74 healthy subjects across 25–1,500 mg; target plasma concentrations were reached.
In Phase 2 studies in COVID-19 and IBD, CD4 helper and CD8 cytotoxic T-cell counts rose into the healthy range, which the company describes as the drug's established mode of action.
Type 2 Diabetes (preclinical): PNB-001 lowered blood glucose by releasing insulin, with insulin release increased by more than 400% in diabetic animals and an effect lasting more than 10 hours in the oral glucose tolerance test. The company describes it as the first small-molecule, non-peptide incretin.
Dementia (preclinical): CCK-mediated acetylcholine release improved learning and memory in rodent water-maze studies, with no cardiotoxicity seen.
- Development
Synthesis established under non-GMP and GMP conditions and optimised to multi-kilogram scale; 50 mg and 100 mg hard gelatin capsules manufactured under GMP.
GLP regulatory toxicology and safety pharmacology (cardiac, renal, respiratory, neuro) in rats and dogs, per ICH guidelines. No inhibition of CYP3A4, CYP2C9 or CYP1A2 up to 10 µM, or CYP2C19 up to 3 µM.
- Intellectual property
- Patents filed in the US, Europe and rest of world; USPTO patent issued 28 December 2014. Composition-of-matter protection to 2037; an immune-use patent extends protection to 2041.
Interested in a programme?
PNB Vesper welcomes discussions on clinical development, licensing, co-development and investment for any molecule in the pipeline.
